Conference Reports for NATAP
Back
 
DDW
Digestive Disease Week
May 21-24, 2006, Los Angeles
Consensus IFN vs Pegasys for 72 Wks in Peg/RBV Relapsers
- (06/12/06)
 
Consensus IFN for Peg/RBV Nonresponders in Germany
- (06/12/06)
 
Hi-Dose Consensus IFN in Prior Peg/RBV Users
- (06/12/06)
 
Consensus Interferon in Peg/RBV Relapsers & Nonresponders in Dallas: 48 weeks end of treatment viral response
- (06/12/06)
 
The Impact of Growth Factors on Pegylated Interferon alfa-2b and Ribavirin Dose Reduction in Patients Treated for Genotype 1 Chronic Hepatitis C
- (06/06/06)
 
Preclinical Characteristics of ITMN-191, an Orally Active Inhibitor of the HCV NS3/4A Protease Nominated for Preclinical Development
- (06/06/06)
 
Pharmacokinetic Analysis and Liver Concentrations of a Series of Macrocyclic Peptidomimetic Inhibitors of HCV NS3/4A Protease: Identification of ITMN-191, a Potent NS3/4A Protease Inhibitor with High Liver Exposure Across Multiple Species
- (06/06/06)
 
Growth Factors Versus Dose Reduction for Pegylated Interferon alfa-2b and Ribavirin-Associated Neutropenia and Anemia in HIV/HCV Co-Infected Patients
- (06/06/06)
 
The Effect of Liver Fibrosis and Cirrhosis on SVR in 4913 Patients With Hepatitis C: Results From The WIN-R Trial
- (06/05/06)
 
Affect of Viral Load on SVR Rates to PegIntron/RBV in Genotype 1 Patients in WIN-R Study
- (06/05/06)
 
Differences In Treatment Outcome To Antiviral Therapy Based On Genotype And Viral Load In Hepatitis C Genotypes 2 And 3 In The WIN-R Trial
- (06/02/06)
 
Safety and Efficacy of Adefovir Dipivoxil in Patients with Lamivudine-Resistant Chronic HBV Undergoing Liver Transplantation
- (05/26/06)
 
A COMPARATIVE TRIAL OF TELBIVUDINE AND ADEFOVIR DIPIVOXIL FOR TREATMENT OF HBeAg-POSITIVE, COMPENSATED CHRONIC HEPATITIS B: 24 WEEK RESULTS
- (05/26/06)
 
Predictive Factors for Exacerbation of Hepatitis B After Discontinuation of Oral Therapy in HBeAg-Negative Patients
- (05/26/06)
 
Entecavir 96 Weeks in Lamivudine-Refractory HBeAg(+): efficacy, safety, resistance
- (05/26/06)
 
NM283 + Peg: differences in response between treatment naives & nonresponders; dose reductions for safety concerns
- (05/26/06)
 
HCV-796, new HCV non-nucleoside- 14 day study
- (05/26/06)
 
"Week 12 Antiviral Activity of Higher Doses of albumin interferon alfa-2b (Albuferon) Combined with Ribavirin in Non-responders to Prior Interferon Based Therapy for Chronic HCV-Infection"
- (05/25/06)
 
Entecavir (ETV) Demonstrates Consistent Responses Throughout Baseline Disease and Demographic Subgroups for the Treatment of Lamivudine-Refractory (LVD-ref) HBeAg(+) Patients with Chronic Hepatitis B
- (05/25/06)
 
Final Analysis of Virological Outcomes and Resistance During 5 Years of adefovir Dipivoxil Monotherapy in HBeAg-Negative Patients
- (05/25/06)
 
96-Week Viral Suppression Data From Two Studies Presented For BARACLUDE (entecavir) In Chronically-Infected Hepatitis B Patients
- (05/24/06)
 
Results from a Cost-Effectiveness Study Demonstrate Positive Economic Impact with PEGASYS Treatment
- (05/24/06)
 
G-CSF is safe and improves adherence and SVR in HCV patients with genotype 1 who develop Peg-IFNa-2b related severe neutropenia
- (05/24/06)
 
African-Americans' response to Interferon: preliminary results from Virahep C Study
- (05/24/06)
 
VX-950 HCV Protease Inhibitor + Pegasys/RBV: 28 days study results in treatment-naive
- (05/24/06)
 
ViroPharma Announces Presentation of HCV-796 Phase 1b Data at Digestive Disease Week
- (05/23/06)
 
HCV Protease ITMN 191, In Vitro Resistance -
- (05/23/06)
 
High Dose Albuferon -early data
- (05/23/06)
 
Hepatitis Patients at Risk for Accidental Acetaminophen Toxicity
- (05/23/06)
 
Reliable early prediction of viral relapse by detection of minimal residual hepatitis C viremia at treatment week 12 with Sensitive HCV Viral load Test
- (05/22/06)
 
High Prevalence of Hepatitis C Virus Infection Among Russian Immigrants in the New York City Metropolitan Area: Results of A Community-Based Screening Program
- (05/22/06)
 
Noninvasive Biomarker Test for Fatty Liver
- (05/22/06)
 
Researchers Report Results for 28-day Phase II Study of VX-950 in Combination with Pegylated Interferon and Ribavirin in Hepatitis C Patients
- (05/22/06)
 
The prevalence of metabolic syndrome (53%) in veterans with chronic hepatitis C virus
- (05/22/06)